Dose dense Dreifach*Melphalan100 for multiple myeloma.

被引：0
|
作者：
Berz, David
McCormack, Elise M.
Winer, Eric S.
Karwan, Patricia
Colvin, Gerald
Rathore, Ritesh
Lum, Larry
Abedi, Mehrdad
Elfenbein, Gerald
Quesenberry, Peter J.
机构：
[1] Brown Univ, Providence, RI 02912 USA
[2] Roger Williams Med Ctr, Providence, RI USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.5465.5465
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5465
引用
收藏
页码：462B / 462B
页数：1
相关论文
共 50 条
  • [21] ASCT and high-dose melphalan in multiple myeloma
    Sharma, Sharan Prakash
    LANCET ONCOLOGY, 2014, 15 (11): : E481 - E481
  • [22] Multiple myeloma.
    Raje N.
    Anderson K.C.
    Current Treatment Options in Oncology, 2000, 1 (1) : 73 - 82
  • [23] Outpatient high dose melphalan in multiple myeloma patients
    Medoff, E
    Kassar, M
    Seropian, S
    Cooper, D
    BONE MARROW TRANSPLANTATION, 2005, 35 : S248 - S248
  • [24] High-dose melphalan in patients with multiple myeloma
    Moreau, P
    Le Bonniec, M
    Harousseau, JL
    BULLETIN DU CANCER, 1999, 86 (03) : 283 - 288
  • [25] HIGH-DOSE MELPHALAN FOR MULTIPLE-MYELOMA
    CAVO, M
    BACCARANI, M
    GOBBI, M
    TURA, S
    LANCET, 1983, 2 (8360): : 1194 - 1194
  • [26] Mitoxantrone and melphalan as conditioning regimen for autologous stem cell transplant for multiple myeloma.
    Beaven, Anne W.
    Comeau, Terrance
    Sharf, Andrew
    Moore, Dominic T.
    Serody, Jonathan
    Shea, Thomas C.
    Gabriel, Don A.
    BLOOD, 2006, 108 (11) : 834A - 834A
  • [27] Efficacy of low dose thalidomide (T) in multiple myeloma.
    Durie, BGM
    Stepan, DE
    BLOOD, 1999, 94 (10) : 316A - 316A
  • [28] Reduced intensity conditioning with thiotepa, fludarabine and melphalan for allogeneic transplantation in multiple myeloma.
    Majolino, I
    Arana, MG
    Riccardi, M
    Locasciulli, A
    Bacigalupo, A
    Di Bartolomeo, P
    Scimè, R
    Olivieri, A
    Narni, F
    De Fabritiis, P
    Corradini, P
    BLOOD, 2003, 102 (11) : 465B - 465B
  • [29] Arsenic trioxide with ascorbic acid and high-dose melphalan for autologous hematopoietic stem cell transplantation for multiple myeloma.
    Qazilbash, Muzaffar H.
    Saliba, Rima M.
    Davis, Marilyn S.
    Mendoza, Floralyn L.
    Hosing, Chitra
    Couriel, Daniel R.
    De Lima, Marcos
    Kebriaei, Partow
    Weber, Donna M.
    Wang, Michael
    Alousi, Arnin M.
    Matthes, Steven G.
    Jones, Roy B.
    Champlin, Richard E.
    Giralt, Sergio A.
    BLOOD, 2006, 108 (11) : 881A - 881A
  • [30] Influence of timing allogeneic stem cell transplantation after dose-reduced melphalan/fludarabine conditioning in multiple myeloma.
    Kroger, N
    Perez-Simon, J
    Myint, H
    Klingemann, H
    Shimoni, A
    Nagler, A
    Martino, R
    Alegre, A
    Tomas, J
    Schwerdtfeger, R
    Kiehl, M
    Fauser, A
    Sayer, HG
    de Leon, A
    Beyer, J
    Zabelina, T
    Ayuk, F
    San Miguel, J
    Brand, R
    Zander, A
    BLOOD, 2003, 102 (11) : 728A - 728A
12345